Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test

The briefing

Moderna shares more than doubled after the company announced initial results from a study of an experimental mRNA cancer treatment. Moderna and Merck are developing intismeran, a cancer vaccine tailored to individual patients' tumor mutations, paired with Merck's immunotherapy drug Keytruda. Melanoma patients receiving the combination lived longer without cancer returning or metastasizing than those on Keytruda alone, though the companies did not release survival figures.